Laura M Moesbergen

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression

Inge S. van Houdt, Berbel J.R. Sluijter, Laura M Moesbergen et al. · International Journal of Cancer · 2008 · 136 citations · Full text

Mhc Class, Immunology, Pathology +19

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting

Anne Slomp, Laura M Moesbergen, Jianan Gong et al. · Blood Advances · 2019 · 86 citations · Full text

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL

Ingela B. Vikstrom, Anne Slomp, Emma M. Carrington et al. · Cell Death and Disease · 2016 · 56 citations · Full text

Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells

Anne Slomp, Laura M Moesbergen, Eric Eldering et al. · Cell Death and Disease · 2021 · 21 citations · Full text

Immunology, Cell Death, Cancer Biology +17

Expression of c‐FLIP is primarily detected in diffuse large B‐cell lymphoma and Hodgkin’s lymphoma and correlates with lack of caspase 8 activation

Inge S. van Houdt, J. J F Muris, Albertus T. Hesselink et al. · Histopathology · 2007 · 12 citations